Viridian Reports Positive Data from Elegrobart Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 hours ago
0mins
Should l Buy VRDN?
Source: Newsfilter
- Clinical Trial Success: The REVEAL-1 trial demonstrated that Elegrobart achieved proptosis responder rates of 54% and 63% in the Q4W and Q8W dosing groups, respectively, significantly surpassing the 18% in the placebo group, indicating its strong efficacy in treating active thyroid eye disease (TED) and positioning it as a potential first subcutaneous autoinjector treatment.
- Significant Diplopia Improvement: In the Q4W group, 51% of patients achieved complete resolution of diplopia compared to only 16% in the placebo group, enhancing patient quality of life and establishing a competitive edge for Viridian in the TED market.
- Strong Financial Position: Viridian ended Q4 2025 with $875 million in cash, and the company anticipates that existing funds, along with near-term milestone revenues, will support its business plans through profitability, showcasing its financial stability and growth potential.
- Positive Future Outlook: The REVEAL-2 trial is expected to report results in Q2 2026, and Viridian plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027, paving the way for Elegrobart's market launch and further expanding its market share in TED treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.390
Low
14.20
Averages
41.71
High
61.00
Current: 27.390
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viridian Therapeutics Shares Drop 31% Despite Positive Trial Results
- Clinical Trial Results: Viridian Therapeutics announced positive topline data from its elegrobart REVEAL-1 phase 3 clinical trial for active thyroid eye disease, yet shares plummeted approximately 31% in morning trading.
- Primary Endpoint Achieved: The study met its primary endpoint with a statistically significant Q4W proptosis responder rate (PRR), showing 54% and 63% PRR for elegrobart at Q4W and Q8W respectively, compared to 18% for placebo.
- Future Plans: The company expects to release topline data from REVEAL-2, the second pivotal phase 3 trial for elegrobart, in the second quarter of 2026, indicating confidence in the product's potential.
- FDA Application Timeline: Viridian plans to submit a Biologics License Application to the U.S. FDA for elegrobart in the first quarter of 2027, highlighting its strategic roadmap for market entry.
See More
Viridian Therapeutics Stock Plummets 35.3% Following Release of Late-Stage Trial Results for Thyroid Eye Disease Treatment
- Stock Performance: Viridian Therapeutics shares fell by 35.3% following the release of late-stage trial data.
- Drug Focus: The decline in stock price is linked to the company's thyroid eye disease drug.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Viridian Therapeutics Shares Plunge 32% Following Phase 3 Trial Results for Elegrobart
- Trial Results Overview: Viridian Therapeutics reported that the phase 3 trial for elegrobart met its primary endpoint for treating thyroid eye disease, yet the stock plummeted approximately 32%, indicating that investor expectations were not met despite the positive results.
- Efficacy Data Analysis: In the four-week dosing group, the responder rate for elegrobart was 54%, compared to 18% for the placebo; in the eight-week group, the rates were 64% and 18%, respectively, highlighting the drug's potential efficacy but falling short of market expectations.
- Diplopia Improvement Rates: At week 24, 51% of patients receiving elegrobart every four weeks achieved complete resolution of diplopia, while 28% did so in the eight-week group, compared to only 16% in the placebo group, indicating a significant advantage in symptom improvement for elegrobart.
- Future Plans and Market Reaction: Viridian anticipates submitting a Biologics License Application (BLA) for elegrobart in Q1 2027; however, Oppenheimer's analyst expressed disappointment with the overall efficacy profile, which may negatively impact future market performance.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
Viridian Therapeutics Shares Drop 31% Despite Positive Trial Results
- Clinical Trial Results: Viridian Therapeutics announced positive topline data from its elegrobart REVEAL-1 phase 3 clinical trial for active thyroid eye disease, yet shares plummeted approximately 31% in morning trading.
- Primary Endpoint Achieved: The study met its primary endpoint with a statistically significant Q4W proptosis responder rate (PRR), showing 54% and 63% PRR for elegrobart at Q4W and Q8W respectively, compared to 18% for placebo.
- Future Plans: The company expects to release topline data from REVEAL-2, the second pivotal phase 3 trial for elegrobart, in the second quarter of 2026, indicating confidence in the product's potential.
- FDA Application Timeline: Viridian plans to submit a Biologics License Application to the U.S. FDA for elegrobart in the first quarter of 2027, highlighting its strategic roadmap for market entry.
See More
Viridian Therapeutics Stock Plummets 35.3% Following Release of Late-Stage Trial Results for Thyroid Eye Disease Treatment
- Stock Performance: Viridian Therapeutics shares fell by 35.3% following the release of late-stage trial data.
- Drug Focus: The decline in stock price is linked to the company's thyroid eye disease drug.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Viridian Therapeutics Shares Plunge 32% Following Phase 3 Trial Results for Elegrobart
- Trial Results Overview: Viridian Therapeutics reported that the phase 3 trial for elegrobart met its primary endpoint for treating thyroid eye disease, yet the stock plummeted approximately 32%, indicating that investor expectations were not met despite the positive results.
- Efficacy Data Analysis: In the four-week dosing group, the responder rate for elegrobart was 54%, compared to 18% for the placebo; in the eight-week group, the rates were 64% and 18%, respectively, highlighting the drug's potential efficacy but falling short of market expectations.
- Diplopia Improvement Rates: At week 24, 51% of patients receiving elegrobart every four weeks achieved complete resolution of diplopia, while 28% did so in the eight-week group, compared to only 16% in the placebo group, indicating a significant advantage in symptom improvement for elegrobart.
- Future Plans and Market Reaction: Viridian anticipates submitting a Biologics License Application (BLA) for elegrobart in Q1 2027; however, Oppenheimer's analyst expressed disappointment with the overall efficacy profile, which may negatively impact future market performance.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
